Quince Therapeutics, Inc. · NASDAQ:QNCX

Quince Therapeutics — Technical Presentation (May 2026)

16 slides from Quince Therapeutics's technical presentation, May 2026

  1. Slide 1: Open Label, Phase 2a Exploratory Study of Inhaled Sirolimus (LAM-001) in Pulmonary Hypertension

    An Open Label, Phase 2a Exploratory Study of Inhaled Sirolimus (LAM-001) for the Treatment of Pulmonary Hypertension Paul B. Yu1, Aaron B. Waxman2, Phillip Joseph3, Franz Rischard4, Adriano Tonelli5, Fraz A. Ismat6, Patrick D. Sarmiere7, Joan Edwards7, Joel Hale7, Keith Fandrick7, Brigette Roberts7

  2. Slide 2: Disclaimers

    Disclaimers • Paul B. Yu has served as a consultant for Orphai Therapeutics, Inc (New Haven, CT), Keros Therapeutics (Waltham, MA), Ingenia Therapeutics (Watertown, MA), and has received research funding from Pfizer, Inc. (New York, NY), Gossamer Bio (San Diego, CA), and Regeneron Pharmaceutical (Ta

  3. Slide 3: mTOR is a master integrator of metabolic state and environmental stress

    mTOR is a master integrator of metabolic state and environmental stress that regulates smooth muscle cell proliferation, fibrosis and inflammation PI3K - Akt mTOR HIF-1⍺ Rapamycin mTORC1 mTORC2 p70S6K 4E-BP1 HIF-1⍺ NOTCH NF-𝛋B STAT3 SGK1 Slug Smooth Muscle Cell Fibrosis Inflammation Endothelial…

  4. Slide 4: Translational and Pre-Clinical Validation of mTOR as a PH target

    Translational and Pre-Clinical Validation of mTOR as a PH target Rapamycin inhibits mTOR, which is Activated in PH Rapamycin Reverses Vascular Remodeling and Improves Hemodynamics Rapamycin is effective in multiple pre-clinical models of PH IPAH distal arteries have an activated mTOR signature Monoc

  5. Slide 5: Early clinical evidence that mTOR Inhibition is effective in PAH

    Early clinical evidence that mTOR Inhibition is effective in PAH Oral Everolimus IV-nab-Sirolimus (ABI-009) 1200 350 6 months, Pre, 1012 298 1000 300 Pre, 236 250 800 6 months, PVR 6MWD PVR, dyn s cm-5 663 200 -19% +107m 6MWD, m 600 150 400 PVR 6MWD 100 200 -31% +62m 50 0 0 Pre 6 months Pre 6 months

  6. Slide 6: Limitations of Systemic Therapy with Oral Rapamycin

    Limitations of Systemic Therapy Systemic Exposure with Significant Safety Profile: Prohibitive systemic toxicities with oral with Oral Rapamycin rapamycin Oral Rapamune® Key Label Warnings and Precautions: Angioedema, Fluid Accumulation and Impairment of Wound Healing, Hyperlipidemia, Decline in Ren

  7. Slide 7: NCT05798923: Phase 2A Trial of LAM-001 in PAH and PH-ILD

    NCT05798923: Phase 2A Trial of LAM-001 (rapamycin DPI) in PAH and PH-ILD Week 0 Week 24 10 Patients; 100 g LAM-001 qd + SOC Open label iCPET1 iCPET1 Design • Open Label; 24 wks; 4 sites; Invasive Cardiopulmonary Exercise Testing (iCPET)1 Inclusion • >18 yo; WHO Functional Class III; PAH or PH-ILD;

  8. Slide 8: LAM-001 Enrollment Characteristics

    LAM-001 Enrollment Characteristics Subject 1 3 2 16 4 5 7 8 14 10 Age 80 59 63 48 74 65 67 71 65 47 Gender Female Male Female Female Female Female Male Female Male Male PH Group 1 3 5 Idiopathic Idiopathic Systemic Pulmonary Diagnosis PAH Fibrotic IPF Fibrotic Sclerosis Sarcoidosis NSIP NSIP Ambrise

  9. Slide 9: LAM-001: Functional Class Endpoint – All Enrolled

    LAM-001: Functional Class Endpoint – All Enrolled WHO Functional Class Assessment All Completers Improved from WHO FC III to II Subject Group Underlying ILD Baseline Wk 1 Wk 4 Wk 12 Wk 16 Wk 24 Mo 12 OLE 1 1 --- III III III III III 1 3 1 --- III III III III II II II 2 1 --- III III II II II II n/a F

  10. Slide 10: LAM-001: Endpoint Summary By Patient - Completers

    LAM-001: Endpoint Summary By Patient - Completers PAH Individuals PH-ILD Individuals Group 1 1 3 5 Evaluable PH-ILD Systemic Idiopathic Idiopathic Pulmonary Population Individuals Only Diagnosis Sclerosis Fibrotic NSIP Fibrotic NSIP Sarcoidosis Subject 3 2 5 7 14* 10 Mean Median n Mean Median n Chan

  11. Slide 11: Endpoint Summary By Patient (Completers): Baseline vs Weeks

    Endpoint Summary By Patient (Completers): Baseline vs 24 Weeks Mean Change = + 81.3 Mean Change = + 5.4% Median Change = + 60.1 150 Mean Change = + 4.8 700 120 Median Change = + 5% IQR = 155.6 Median Change = + 3.5 IQR = 5 IQR = 8.0 110 600 100 90 125 Consistent improvements or stabilization across

  12. Slide 12: Treatment elicited consistent directionality of effect across multiple endpoints

    Treatment elicited consistent directionality of effect across multiple endpoints + 60.1 m (14.3 m – 169.9 m) + 5% (3% – 8%) + 3.5% (0% – 8%) - 26.6% (-52.3% – 1.9%) - 33.9% (-49.5% – -2.3%) - 46.9% (-54.3% – -8.9%) median change (IQR) 12

  13. Slide 13: Safety Summary through 24-Weeks

    Safety Summary through 24-Weeks LAM-001 was well tolerated Drug Related AEs No dose interruptions due to AEs • Grade 1 Productive Cough (n = 1) - Resolving • Grade 2 Cough (n = 1) - Not Resolved • Grade 1 Gingivitis (n = 1) - Resolving No discontinuations due to drug No drug related SAEs

  14. Slide 14: LAM-001 Phase 2A Study Summary

    LAM-001 Phase 2A Study Summary Favorable tolerability in adults with WHO FC III Pulmonary Hypertension on SOC therapy Improvements or Stabilization in VO2Max, PVR, 6MWD, NT-proBNP, and FVC suggest an underlying physiological benefit beyond test variability Shift of all evaluable patients from FC III

  15. Slide 15: Acknowledgements

    Acknowledgements Investigators Aaron B. Waxman, MD, PhD Mass General Brigham - BWH Phillip Joseph, MD Yale Franz Rischard, DO, MSc UA Tucson Adriano Tonelli, MD Cleveland Clinic OrphAI FICC LLC Patrick D. Sarmiere Fraz A. Ismat Joan Edwards Joel Hale Keith Fandrick Brigette Roberts, MD

  16. Slide 16: Rapamycin Targets PH Pathobiology

    Rapamycin Targets PH Pathobiology Extracellular Matrix Rapamycin inhibits pulmonary arterial smooth muscle cell proliferation, fibrosis, and vascular inflammation – all of which contribute to PH remodeling 16 AI-generated image created by the authors. 2026

Quince Therapeutics — Technical Presentation (May 2026) on 6ix